Feb 16, 2010 by Brian Orelli, PhDDon't Invest Like My RelativesSavings bonds are sweet, but at what cost?
Feb 12, 2010 by Brian Orelli, PhDToo Bad It's Not in the "Restructuring" Business$130 million here, $200 million there -- when will the charges end?
Feb 12, 2010 by Brian Orelli, PhDDon't Ignore This Potential BlockbusterFive trials later, Roche's taspoglutide seems like a winner.
Feb 11, 2010 by Brian Orelli, PhDBlockbuster in Hand, It's Time to Show a ProfitElan predicts an operating profit for the first time in nine years.
Feb 11, 2010 by Brian Orelli, PhDA Turnaround Year, But Not in a Good WaySanofi looks flat ... if its lucky.
Feb 11, 2010 by Brian Orelli, PhDA Wonder Drug With Not-So-Wonderful Side EffectsWonder drug or not, mipomersen's sales will be limited by side effects.
Feb 10, 2010 by Brian Orelli, PhDIcahn's Smiling -- Should We Be?Biogen cuts costs, but has it gone too far?
Feb 9, 2010 by Brian Orelli, PhDBone Up On This Potential BlockbusterAmgen's denosumab passes another test on its way to potential blockbuster status.
Feb 9, 2010 by Brian Orelli, PhDPfizer's Slippery SlopeDiscount cards for drugs help Pfizer track patients' use.
Feb 9, 2010 by Brian Orelli, PhDWhat Bipartisan Health-Care Reform Means for InvestorsRepublicans and Democrats will debate on TV, but little may come of it.
Feb 8, 2010 by Brian Orelli, PhDAn Earnings Surprise of an Unusual KindIllumina beats management's preliminary revenue announcement.
Feb 4, 2010 by Brian Orelli, PhDSurfing the Wave of the Future: Personalized MedicineMedco buys in to personalized medicine.
Feb 4, 2010 by Brian Orelli, PhDGlaxo Brings Home the BaconSwine flu gives GlaxoSmithKline the boost, but how long will it last?
Feb 3, 2010 by Brian Orelli, PhDPfizer's Hedge Pays OffFDA wants more data from Pfizer's partner, Protalix.
Feb 3, 2010 by Brian Orelli, PhDWyeth Can't Save PfizerNot much earnings growth, but the price is right.
Feb 2, 2010 by Brian Orelli, PhDFoolish Forecast: First Look at Pfizer PlusViews you can use for tomorrow's news.
Feb 2, 2010 by Brian Orelli, PhDShaking Up the Biotech IndustryA judge will decide if genes are patentable or not.
Feb 1, 2010 by Brian Orelli, PhDNow That's Some Expensive Risk MitigationBoston Scientific avoids a trial -- at a cost.
